History, Pharmacology and Mechanism - Stephen Dickson, BSC (hons) MRPharmS (2021 Conference) (LDN, low dose naltrexone)

LDN Research Trust 2021 Conference - Friday Morning

Cory Tichauer, ND - LDN and Lyme Disease II (2017 Conference) (LDN, low dose naltrexone)

Armin Schwarzbach, MD, PhD - Lyme Borreliosis (2017 Conference) (LDN, low dose naltrexone)

Lyme borreliosis symptoms and coinfections, modern lab tests, new therapy options in chronic Lyme disease

Cory Tichauer, ND - Immune Dysfunction in Post-Treatment Lyme Disease: Using Naltrexone to Balance Chronic Inflammation II (2019 Conference) (LDN, low dose naltrexone)

Armin Schwarzbach, PhD, MD - Infections in Cancer and Autoimmune Disorders II (2019 Conference) (LDN, low dose naltrexone)

Sajad Zalzala, MD - What Patients Need to Know About Telemedicine (2019 Conference) (LDN, low dose naltrexone)

Sajad Zalzala, MD discusses what telemedicine is, its use and benefits, and about using LDN Direct telemedicine/LDN prescription business. Some telemedicine regulations are presented, as well as common conditions treated with LDN

LDN 2019 Conference - Friday Afternoon Q&A (2019 Conference) (LDN, low dose naltrexone)

Presentations on the below and questions were asked in relation to:

Pamela Smith, MD - LDN Use in Cognitive Decline, Lyme Disease, and Hashimoto’s Thyroiditis (2019 Conference) (LDN, low dose naltrexone)

Kent Holtorf, MD - LDN should be considered a first-line therapy for CFS/FM (2019 Conference) (LDN, low dose naltrexone)

Dana Keaton, ND - The scope of patient selection for LDN (2019 Conference) (LDN, low dose naltrexone)